PHAXIAM Therapeutics SA ADR PHXM Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$3.10 unchanged at close Nov 6
Last close · Previous close $3.10
- Market cap
- $9.62MAt the Nov 6 close
- Dividend yield
- NoneLast 12 months
Price chart
$3.10unchangedPast month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$3.10Nov 5
- Volume0.00Nov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume0.00Last 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $3.10 to $3.10; now $3.10
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
PHXM beat the S&P 500 in both periods.
| Period | PHXM and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PHXM: unchanged S&P 500: down 5.6% | PHXM beat the S&P 500 by 5.6 percentage points Beat |
| 3M | PHXM: unchanged S&P 500: down 4.1% | PHXM beat the S&P 500 by 4.1 percentage points Beat |
PHXM beat the S&P 500 in both periods.
| Period | PHXM and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PHXM: unchanged S&P 500: down 5.6% | PHXM beat the S&P 500 by 5.6 percentage points Beat |
| 3M | PHXM: unchanged S&P 500: down 4.3% | PHXM beat the S&P 500 by 4.3 percentage points Beat |
All-time high
$3.10
Closing high on .
Split-adjusted daily closes since Jun 29, 2023.
Stock splits
PHXM hasn’t split since its price history begins in 2023.
Valuation
The Nov 6 close compared with reported results. 12-month figures aren’t available until four quarters are reported. Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
Not available
12-month figures aren’t available until four quarters are reported.
Other valuation measures
- 0.2×Book value as of Jun 30, 2023
Price relative to accounting equity (book value) per share on the Jun 30, 2023 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −$1.64MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2023 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own PHXM DCF in Excel. Value PHAXIAM Therapeutics SA ADR with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY23, the quarter ended Jun 30, 2023, and balance-sheet figures are as of Jun 30, 2023. 12-month figures aren’t available until four quarters are reported.
Revenue and net income
12-month figures aren’t available until four quarters are reported.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY20 (Dec 31, 2020) | Not reported | Not reported | Not reported |
| Q2 FY21 (Jun 30, 2021) | Not reported | Not reported | Not reported |
| Q4 FY21 (Dec 31, 2021) | Not reported | Not reported | Not reported |
| Q2 FY22 (Jun 30, 2022) | Not reported | Not reported | Not reported |
| Q4 FY22 (Dec 31, 2022) | Not reported | Not reported | Not reported |
| Q2 FY23 (Jun 30, 2023) | Not reported | Not reported | Not reported |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $4.53M | −$89.39M | −$48.66 |
| FY21 (Dec 31, 2021) | $4.75M | −$61.13M | −$25.80 |
| FY22 (Dec 31, 2022) | $32.98M | −$242.55K | −$0.11 |
Margins
- Gross
- Operating
- Net
The lines show each quarter. What margins tell you
Cash flow
12-month figures aren’t available until four quarters are reported.
Shareholder returns
12-month figures aren’t available until four quarters are reported.
Balance sheet
- $27.68MAs of Jun 30, 2023
Cash plus short- and long-term marketable securities on the Jun 30, 2023 balance sheet.
- Total debt$16.64MAs of Jun 30, 2023
- Net cash$11.04MAs of Jun 30, 2023
- 1.78As of Jun 30, 2023
Current assets divided by current liabilities on the Jun 30, 2023 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.41As of Jun 30, 2023
Total debt divided by shareholders’ equity on the Jun 30, 2023 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
12-month figures aren’t available until four quarters are reported.
About PHAXIAM Therapeutics SA ADR
PHAXIAM Therapeutics SA ADR
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- France
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
PHXM news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
PHXM stock FAQ
What is PHXM stock’s price today?
PHAXIAM Therapeutics SA ADR (PHXM) traded at $3.10 at the close on , unchanged from the previous close of $3.10. Over the past 52 weeks it has traded between $3.10 and $3.10.
What is PHAXIAM Therapeutics SA ADR’s market cap?
PHAXIAM Therapeutics SA ADR’s market capitalization is about $9.6 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $3.10 (how market cap works). PHAXIAM Therapeutics SA ADR reported 3.10M shares outstanding at the end of its latest quarter ().
Does PHXM pay a dividend?
PHAXIAM Therapeutics SA ADR hasn’t paid a dividend in the last twelve months.
What is PHXM’s 52-week high and low?
Over the past 52 weeks PHXM has traded as low as $3.10 and as high as $3.10. At $3.10 at the close on , it is 0.0% below that high and 0.0% above the low.
What is PHXM’s all-time high?
PHXM’s highest closing price was $3.10 on , adjusted for stock splits.
Has PHXM stock ever split?
No. PHXM hasn’t split since its price history begins in 2023.
What sector and industry is PHAXIAM Therapeutics SA ADR in?
PHAXIAM Therapeutics SA ADR is in the Healthcare sector and the Biotechnology industry, and is headquartered in France.
What exchange does PHXM trade on?
PHAXIAM Therapeutics SA ADR trades on the Nasdaq under the ticker symbol PHXM. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.